Table 5.

Association between CCC and TA and incidence rate of treatment with ASMs

Category	Variable	Beta	SE	IRR (95% CI)*	P value
TA
	Tracheostomy	−1.25	0.49	0.29 (0.11 to 0.75)	0.011
	Evacuation tube	0.87	0.34	2.39 (1.22 to 4.67)	0.011
	Gastrostomy	0.83	0.12	2.28 (1.80 to 2.91)	<0.001
	Renal support	0.18	0.34	1.20 (0.62 to 2.33)	0.596
CCC
	Cardiovascular	−0.11	0.15	0.90 (0.66 to 1.21)	0.467
	Metabolic	−0.62	0.18	0.54 (0.38 to 0.76)	<0.001
	Neonatal	0.67	0.16	1.95 (1.42 to 2.68)	<0.001
	Gastrointestinal	−0.25	0.22	0.78 (0.50 to 1.20)	0.255
	Haemat/immunol	0.15	0.21	1.16 (0.77 to 1.74)	0.472
	Respiratory	0.27	0.20	1.31 (0.89 to 1.92)	0.172
	Malignancy	−1.06	0.22	0.35 (0.23 to 0.53)	<0.001
	Renal/uologic	0.01	0.22	1.01 (0.66 to 1.54)	0.981
	Genetic/congenital	0.58	0.14	1.78 (1.37 to 2.33)	<0.001

*Adjusted for age and gender.

ASM, acid-suppressing medication; CCC, complex, chronic conditions; IRR, incidence rate ratio; TA, technology assistance.